Law360 (February 25, 2011, 4:56 PM EST) -- A New Jersey federal judge on Tuesday tossed generics maker Mylan Inc.'s inequitable conduct defenses in a patent infringement suit brought by Teva Pharmaceutical Industries Ltd. over efforts to make a copycat version of Parkinson's disease drug Azilect.
Judge Jose L. Linares of the U.S. District Court for the District of New Jersey granted Teva's motion to dismiss Mylan's counterclaims and affirmative defense alleging that U.S. Patent Number 5,453,446 was unenforceable due to the plaintiff intentionally misleading the examiner during the prosecution of the asserted patent...
Mylan Claims Fall In IP Suit Over Generic Azilect
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
